Cargando…

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma

(1) Background: Biliary tract cancers (BTCs) are a heterogeneous group of neoplasms with dismal prognosis and the role of adjuvant chemoradiotherapy in high-risk resected patients is unclear. (2) Methods: We retrospectively analyzed the outcomes of BTC patients who received curative intent surgery w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palloni, Andrea, Bisello, Silvia, Maggio, Ilaria, Massucci, Maria, Galuppi, Andrea, Di Federico, Alessandro, Rizzo, Alessandro, Ricci, Angela Dalia, Siepe, Giambattista, Morganti, Alessio Giuseppe, Brandi, Giovanni, Frega, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217181/ https://www.ncbi.nlm.nih.gov/pubmed/37232816 http://dx.doi.org/10.3390/curroncol30050358

Ejemplares similares

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma
por: Sugiura, Teiichi, et al.
Publicado: (2020)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
por: Frega, Giorgio, et al.
Publicado: (2020)

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
por: Carloni, Riccardo, et al.
Publicado: (2022)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

Novel Targeted Therapies for Advanced Cholangiocarcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
por: Vasuri, Francesco, et al.
Publicado: (2023)

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
por: De Lorenzo, Stefania, et al.
Publicado: (2018)

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report
por: Massucci, Maria, et al.
Publicado: (2021)

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Definition of fields margins for the optimized 2D radiotherapy of prostate carcinoma
por: Buwenge, Milly, et al.
Publicado: (2019)

Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma
por: Nanni, Cristina, et al.
Publicado: (2023)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Unsectable cholangiocarcinoma: Additional therapy to chemoradiotherapy
por: Chaiyasit, Kamon, et al.
Publicado: (2013)

Impact of Microscopically Positive (≤1 mm) Distal Margins on Disease Recurrence in Rectal Cancer Treated by Neoadjuvant Chemoradiotherapy
por: Sorrentino, Luca, et al.
Publicado: (2023)

CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report
por: Medici, Federica, et al.
Publicado: (2022)

COVID-19 Pandemic-Adapted Radiotherapy Guidelines: Are They Really Followed?
por: Galofaro, Elena, et al.
Publicado: (2021)

Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels
por: Zheng, Xuan, et al.
Publicado: (2018)

Impact of Positive Radial Margin on Recurrence and Survival in Perihilar Cholangiocarcinoma
por: D’Amico, Francesco Enrico, et al.
Publicado: (2022)

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
por: Di Marco, Mariacristina, et al.
Publicado: (2020)

R1 Vascular or Parenchymal Margins: What Is the Impact after Resection of Intrahepatic Cholangiocarcinoma?
por: Mabilia, Andrea, et al.
Publicado: (2022)

Adjuvant Therapy for a Microscopically Incomplete Resection Margin after an Esophagectomy for Esophageal Squamous Cell Carcinoma
por: Qiu, Bo, et al.
Publicado: (2017)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021)

A “SHort course Accelerated RadiatiON therapy” (SHARON) During and Beyond the COVID-19 Pandemic
por: Morganti, Alessio G., et al.
Publicado: (2022)

Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review
por: Bisello, Silvia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p2vlnght73animeps90f03ar6t